Toggle Main Menu Toggle Search

Open Access padlockePrints

Increasing neutrophil F-actin CD11b exposure in Type 2 diabetes

Lookup NU author(s): Dr Andrew Advani, Emerita Professor Sally Marshall, Dr Trevor Thomas

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Background: Leukocyte dysfunction contributes to the pathogenesis of diabetic vascular complications. Neutrophils adhere to the endothelium through the β2integrin CD11b/CD18. In Type 2 diabetes, neutrophil surface CD11b expression is increased and is associated with impaired actin polymerization. This study aimed to determine whether increasing neutrophil actin polymerization could correct the defect in CD11b exposure. Design: Neutrophil actin polymerization was stimulated with the tyrosine phosphatase inhibitor phenylarsine oxide (PAO), and cytoskeletal phosphotyrosine was monitored by immunoblotting Triton X-100 insoluble fractions of cells. Neutrophil F-actin was measured with phalloidin-FITC staining, and surface CD11b expression was determined with anti-CD11b-PE before analysis with flow cytometry. Results: Phenylarsine oxide caused an increase in phosphotyrosine in neutrophils from both patients with Type 2 diabetes (DM) and controls (NC) (-fold increase: NC, 1.43 ± 0.16; DM, 1.46 ± 0.10). The response to PAO in terms of phalloidin-binding was impaired in neutrophils from patients [phalloidin-FITC MFI area under the curve, NC 200 ± 5 (× 10 3), DM 124 ± 9 (× 103), P < 0.0001]. Phenylarsine oxide at concentrations < 10 μmol L-1 also caused loss of CD11b from neutrophil surfaces that was impaired in samples from patients [CD11b sites area under the curve NC 90 ± 6 (× 10 3), DM 121 ± 9 (× 103), P < 0.002]. However, in neutrophils from patients, incubation with PAO at a concentration of > 10 μmol L-1 caused a significant increase in intracellular F-actin and CD11b downregulation equivalent to that observed in controls. Conclusion: In Type 2 diabetes, impaired neutrophil actin polymerization even in response to increasing cytoskeletal phophotyrosine suggests a downstream defect. Furthermore, increasing actin polymerization, above a minimum threshold level, corrects the defect in integrin exposure. Correction of the actin polymerization defect in Type 2 diabetes could improve the prognosis of diabetic vascular complications.


Publication metadata

Author(s): Advani A, Marshall SM, Thomas TH

Publication type: Article

Publication status: Published

Journal: European Journal of Clinical Investigation

Year: 2004

Volume: 34

Issue: 5

Pages: 358-364

ISSN (print): 0014-2972

ISSN (electronic): 1365-2362

Publisher: Wiley-Blackwell

URL: http://dx.doi.org/10.1111/j.1365-2362.2004.01346.x

DOI: 10.1111/j.1365-2362.2004.01346.x

PubMed id: 15147333


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share